Bicycle Therapeutics (BCYC) Free Cash Flow (2018 - 2026)

Bicycle Therapeutics (BCYC) has 9 years of Free Cash Flow data on file, last reported at -$49.9 million in Q2 2026.

• Quarterly Free Cash Flow rose 31.95% year-over-year to -$49.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$208.3 million (up 0.96% YoY) and the FY2025 annual result came in at -$252.0 million, down 51.86% from the prior year.
• Free Cash Flow rose to -$49.9 million in Q2 2026, from -$66.6 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $33.8 million in Q2 2023 to a low of -$87.0 million in Q1 2025.
• A 5-year average of -$39.1 million and a median of -$42.7 million in 2024 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2023 — Free Cash Flow soared 201.47% — and 2024, when it plunged 2537.0%.
• Tracing BCYC's Free Cash Flow over 5 years: stood at -$31.8 million in 2022, then tumbled by 49.07% to -$47.3 million in 2023, then jumped by 79.37% to -$9.8 million in 2024, then sank by 104.01% to -$19.9 million in 2025, then tumbled by 150.36% to -$49.9 million in 2026.
• The last three Free Cash Flow figures came in at -$49.9 million (Q2 2026), -$66.6 million (Q1 2026), and -$19.9 million (Q4 2025), per Business Quant data.